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Interleukin 10 (IL-10), originally defined as cytokine synthesis
inhibitory factor produced by type 2 helper T-lymphocytes
(Fiorentino et al, 1989), has subsequently been described as a poten-
tially immunosuppressive cytokine. By interfering with the co-stimu-
latory function of antigen-presenting cells (APCs), e.g. regulation of
class II MHC expression of monocytes (deWaal Malefyt et al, 1991),
and co-stimulatory molecule expression of macrophages (Ding et al,
1993), IL-10 reduces antigen-specific T-cell proliferation. Moreover,
a direct effect of IL-10 on IL-2 production by activated T-cells has
been observed (deWaal Malefyt et al, 1993). It has been demon-
strated that IL-10 blocks the development of predendritic cells into
mature dendritic cells (DCs) in vitro (Buelens et al, 1997).
This IL-10-mediated immunosuppression represents an important
escape mechanism of tumours and needs further clinical investigation.
Therefore, using a highly sensitive enzyme-linked immuno-
sorbent assay (ELISA) recognizing both human and viral IL-10,
we measured the serum concentrations of IL-10 in 80 consecutive
patients with a fully documented clinicopathological history of
metastatic renal cell carcinoma seen in our institution since May
1990. We assessed the potential correlation between serum IL-10
levels and the outcome of these patients.
METHODS
Patients and collections of samples
This study was approved by the institutional review board of the
Medizinische Hochschule Hannover; written informed consent
was obtained from all patients prior to entry into the study. At this
time, we obtained samples of peripheral blood from 80 consecu-
tive patients with metastatic renal cell carcinoma, seen at our insti-
tution at the Medizinische Hochschule Hannover, Germany since
May 1990. Sera were frozen at —80°C until analysis.
Patient characteristics are summarized in Table 1; all patients
had a Karnovsky performance status ‡ 70%, and presented with
histologically confirmed metastatic renal cell carcinoma and with
clinically progressive disease as demonstrated by standard radio-
graphic procedures. Patients received systemic immunotherapy
with subcutaneous IL-2 and interferon-alpha (Atzpodien et al,
1995); treatment was continued until disease progression occurred.
Survival was measured from start of systemic therapy.
ELISA for IL-10
Pretreatment levels of soluble IL-10 were determined using an
ELISA assay (IL-10, Medgenix, Ratingen, Germany). All analyses
were performed in duplicate, strictly according to the procedures
recommended by the manufacturers, and samples were analysed at
a dilution resulting in measured concentrations within the range
of the standard curves. Normal donor sera showed no measurable
IL-10 serum levels in this assay. Sensitivity was at 0.208pg ml—1
with a range of 0.78—50pg ml—1. Cross-reactivity was specified
with less than 1%.
Statistical analysis
The statistical end point in our analysis was overall survival from
time of entry into the study. We calculated univariate hazard
ratios with 95% confidence intervals, using the Cox proportional
hazards model. The simultaneous prognostic effect of various
factors was determined in a multivariate analysis using a Cox
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proportional hazards model (forward and reverse selection of
variables). The probability of overall survival was plotted over
time according to the method of Kaplan and Meier (Kaplan et al,
1958). Differences in overall survival between groups were tested
as dichotomized prognostic variables. For IL-10, erythrocyte
sedimentation rate (ESR) and haemoglobin, Kaplan—Meier esti-
mates were performed defining the best cut-off value for discrim-
ination between poor and good overall survival. For lactate
dehydrogenase (LDH), the institutional upper normal limits were
chosen as the cut-off (240 U l—1).
RESULTS
Univariate analysis of pretreatment variables and
survival
We analysed the ability of various clinical factors and of serum
levels of soluble IL-10 to predict clinical outcome. The mean
period of follow-up for the surviving patients was 32+ months
(range, 2—80+ months). The median survival of all 80 patients
entering the study was 21+ months.
We calculated univariate P-values with the Kaplan—Meier
model (Table 2). In this analysis, IL-10, LDH, haemoglobin and
ESR had significant prognostic impact on overall survival.
Elevated serum levels of IL-10 (> 1 pg ml—1) were detected in 21
patients and were strongly associated with an unfavourable
outcome. Median survival in these patients was 11+ months as
opposed to patients with low IL-10 levels († 1 pg ml—1, n = 59)
who had a median survival of 27+ months (P < 0.0028).
All other variables investigated (sex, age, time between diag-
nosis and progression, lung metastases, bone metastases, liver
metastases, brain metastases and local relapse) were not statisti-
cally significant for the prediction of patient survival.
Multivariate analysis of risk factors
To identify the most powerful independent predictors, we estab-
lished a multivariate Cox proportional hazards model containing
those factors with significant prognostic value upon univariate
analysis. All four univariate risk factors were found to be
statistically independent: haemoglobin < 10 g dl—1 (P = 0.0005),
ESR ‡ 50 mm h—1 (P = 0.049), serum LDH ‡ 240 U l—1 (P =
0.0233) and serum IL-10 > 1 pg ml—1 (P = 0.0226). The hazard
ratios calculated with a model containing these prognostic factors
are shown in Table 3.
DISCUSSION
Our study demonstrated that elevated pretreatment serum IL-10 is
a potentially powerful and independent predictor of overall
survival in patients with metastatic renal cell carcinoma. Both by
univariate and multivariate analysis, serum IL-10 (P = 0.0226),
serum LDH (P = 0.0233), haemoglobin (P = 0.0005) and ESR
(P = 0.049) were predominant independent predictors of survival;
by demonstrating statistic independence, IL-10 adds new infor-
mation to previously identified risk factors.
Table 1 Patient characteristics
IL-10 ≤ 1 pg ml–1 IL-10 > 1 pg ml–1
Variable nn a n
Patients 80 59 21
Sex
Male 60 44 16
Female 20 15 5
Age (years)
Mean 57 56 57
Range 32–74 37–72 32–74
Metastases
Lung 59 43 16
Bone 23 17 6
Liver 20 13 7
Brain 11 8 3
Tumour sites
12 8 2 4 4
> 1 52 35 17
aSerum IL-10 levels were assayed prior to systemic therapy.
Table 2 Impact of pretreatment serum IL-10 levels and clinical factors on
patient survival in 80 consecutive patients with advanced renal cell
carcinoma by univariate analysis
Variable Categories compareda P-value
Clinical factors
Sex Female vs. male 0.89
Age (years) < 60 vs. ³ 60 0.155
Time between diagnosis > 12 vs. ≤ 12 0.16
and progression
(months)
Haemoglobin (g dl–1) ³ 10 vs. < 10 0.0000
ESR (mm h–1) < 50 vs. ³ 50 0.0004
LDH (U l–1) < 240 vs. ³ 240 0.016
Lung metastases Present vs. absent 0.86
Bone metastases Absent vs. present 0.18
Liver metastases Absent vs. present 0.92
Brain metastases Absent vs. present 0.12
Local relapse Absent vs. present 0.35
IL-10 (pg ml–1) ≤ 1 vs. > 1 0.0028
aFor each variable, the prognostic significance of the first category listed
was assessed by comparing that category with the reference category
(the second category listed).
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Figure 1 Serum IL-10 and survival in 80 patients with metastatic renal cell
carcinoma. Survival curves (Kaplan–Meier estimate) of patients with either
low (≤ 1 pg ml–1) or elevated (> 1 pg ml–1) serum levels of IL-10. P-value was
determined by log rank test. Tick marks represent patients for whom data
were censored.1184 F Wittke et al
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We have shown previously that elevated serum LDH, elevated
ESR and decreased haemoglobin may correlate with tumour load
and with poor outcome in patients with metastatic renal cell carci-
noma (Lopez-H￿nninen et al, 1995).
IL-10 has been detected in different human tumours, e.g. malig-
nant melanoma and renal cell carcinoma (Wang et al, 1995). The
location of the compartment of IL-10 secretion remains to be
identified in humans with malignant disease. Tumour-infiltrating
lymphocytes and tumour cells of renal cell carcinoma themselves
have been detected as source for IL-10 (Dummer et al, 1996;
Knoefel et al, 1997). The reason for the elevated IL-10 production
still remains unclear. The elevated serum IL-10 levels that we
found may be correlated with a high intratumoral IL-10 produc-
tion. As Buer et al (1998) recently demonstrated, IL-10 can be
produced by anergic T-lymphocytes and is able to contribute to
T-cell anergy. Intratumorally produced IL-10 may therefore lead to
anergy of tumour-infiltrating lymphocytes and thereby support
intratumoral tolerance. This may be a reason for rapid progression
of some patients with malignant disease.
Other malignant diseases have been demonstrated to show a
similar mechanism. Thus, elevated serum IL-10 levels have been
demonstrated as a negative prognostic factor in patients with
active non-Hodgkin￿s lymphoma (Blay et al, 1993).
In conclusion, in the present study, elevated pretreatment serum
levels of IL-10 correlate with poor outcome in renal cell carcinoma.
These data may contribute to a better patient selection via risk strat-
ification for future therapeutic trials. This factor may potentially
influence the decision-making of available immunotherapeutic
strategies of patients with metastatic renal cell carcinoma. In addi-
tion, an improved understanding of the pretreatment immuno-
logical status of patients with metastatic renal cell carcinoma may
provide a lead for future therapeutic strategies focusing on the
modulation of this cytokine and/or its receptor structure. Our results
will have to be prospectively confirmed in future controlled studies.
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